Research indexRCT
СТИМУЛЯЦИЯ ИММУНИТЕТА ПРИ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЯХ ЖИВОТНЫХ
Shatmanov, Өсербай, ТУТКЫШБАЙ and 3 others
Animal Health and Biosafety28 Mar 2026Open access
NobleIDark:/48914/w1/20261105/AA4EA89BDOI10.52578/3134-8114-2026-1-299-310
СТИМУЛЯЦИЯ ИММУНИТЕТА ПРИ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЯХ ЖИВОТНЫХ
Shatmanov, Өсербай, ТУТКЫШБАЙ and 3 others · Animal Health and Biosafety · 2026
NobleIDark:/48914/w1/20261105/AA4EA89BDOI10.52578/3134-8114-2026-1-299-310
Abstract
A key characteristic of a tumor is the atypical structure of its tissue and cells compared to normal tissues. The use of animals, particularly dogs with spontaneous tumors, opens up promising prospects for research and the development of effective anticancer agents. One of the most promising directions in immunotherapy for malignant neoplasms in animals is combination therapy. The combination of immunotherapy with traditional methods, such as surgery, chemotherapy, or radiation therapy, can significantly enhance treatment effectiveness. For example, after the main mass of the tumor is removed, immunotherapy can help eliminate remaining microscopic cancer cells and prevent recurrences. Chemotherapy and radiation therapy, when targeting cancer cells, also weaken the activity of normal cells, which can reduce the blood’s immune reserve. The scientific paper describes research on biological material — blood serum from healthy pigs with a high content of specific antibodies that do not harm the body of an animal suffering from a malignant tumor. In the prevention and treatment of malignant tumors, particular attention is given to enhancing the patient’s immune reserve. Immunoglobulins present in the heterologous serum indirectly enhance the activity of the cellular arm of the immune system, activating its ability to recognize and eliminate atypical tumor cells. The paper also presents methods for preparing therapeutic heterologous serum as an adjunctive treatment for malignant neoplasms in animals. Results of the use of heterologous serum in dogs with malignant tumors are provided. A randomized controlled study was conducted to evaluate the effectiveness of heterologous serum in dogs with tumors in the perioperative and postoperative periods. Considering that invasive interventions were conducted in this study, it was approved by the local bioethics committee of the South Kazakhstan University named after M. Auezov (for biomedical research on animals), Protocol No. 5, dated 13.10.2025.